Articles on Longevity Economics, Investments, and Science on Life Span Extension

Interviews with researchers, founders, and policymakers, written for readers who are curious, not credentialed.

Longevity Economics, Longevity Technology & Science Rajnandini Mohapatra Longevity Economics, Longevity Technology & Science Rajnandini Mohapatra

Will the Longevity Industry Create Hyperscaler-type Healthcare Companies? 

Eli Lilly comes to our mind as the first one with its GLP-1 medicine and more preventive medicines in its pipeline. Other large companies like Novo Nordisk, Roche, Pfizer, Johnson & Johnson, Merck, AstraZeneca, and AbbVie are working on preventive medicines.

Read More

Frequently Asked Questions

  • All articles are written by Rajnandini Mohapatra, an independent researcher and writer specializing in the longevity economy, aging science, biotechnology, healthcare innovation, public policy, economics, and investment trends.

  • The blog examines how longevity, science, economics, finance, technology, healthcare, entrepreneurship, and public policy intersect. Content features research-based articles, expert interviews, industry analysis, and commentary on trends shaping longer, healthier lives.

  • Interview guests are chosen for their expertise, achievements, and contributions in longevity-related fields such as aging research, biotechnology, healthcare, investing, entrepreneurship, policy, and innovation.

  • Interviews are typically conducted via email, video calls, or written questionnaires. Discussions address insights, opportunities, challenges, and the future of longevity-related industries and research.

  • Yes. Articles draw on publicly available research, industry reports, academic publications, expert insights, and independent analysis. Sources are cited when appropriate.

  • New articles, interviews, and resources are published regularly as developments arise in longevity science, healthcare, economics, finance, and related fields.

  • No. The content is for educational and informational purposes only and should not be considered medical, financial, legal, or investment advice. Readers should consult qualified professionals before making healthcare or financial decisions.

  • Yes. Reader suggestions are welcome. Please use the Contact page to recommend topics, research areas, or potential interview guests.

  • Yes. Researchers, entrepreneurs, investors, policymakers, and industry leaders interested in contributing are encouraged to reach out through the Contact page.

  • Subscribe by entering your email address in the newsletter signup form. Subscribers receive updates on new articles, interviews, and major developments in the longevity ecosystem.

  • Currently, guest contributions are reviewed on a case-by-case basis. Please contact us with a brief proposal if you are interested in contributing.

  • In addition to subscribing to the newsletter, follow the blog's social media channels to stay connected and receive the latest articles, interviews, and industry insights.